CO2019014212A2 - Métodos de tratamiento para la distonía cervical listado de secuencias - Google Patents
Métodos de tratamiento para la distonía cervical listado de secuenciasInfo
- Publication number
- CO2019014212A2 CO2019014212A2 CONC2019/0014212A CO2019014212A CO2019014212A2 CO 2019014212 A2 CO2019014212 A2 CO 2019014212A2 CO 2019014212 A CO2019014212 A CO 2019014212A CO 2019014212 A2 CO2019014212 A2 CO 2019014212A2
- Authority
- CO
- Colombia
- Prior art keywords
- cervical dystonia
- sequence listing
- treatment methods
- compositions
- injectable compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 206010044074 Torticollis Diseases 0.000 title abstract 2
- 201000002866 cervical dystonia Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000007972 injectable composition Substances 0.000 abstract 2
- 108030001720 Bontoxilysin Proteins 0.000 abstract 1
- 229940053031 botulinum toxin Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508324P | 2017-05-18 | 2017-05-18 | |
| PCT/US2018/033397 WO2018213710A1 (en) | 2017-05-18 | 2018-05-18 | Methods of treatment for cervical dystonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019014212A2 true CO2019014212A2 (es) | 2020-01-17 |
Family
ID=64274745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0014212A CO2019014212A2 (es) | 2017-05-18 | 2019-12-16 | Métodos de tratamiento para la distonía cervical listado de secuencias |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200179498A1 (enExample) |
| EP (1) | EP3624819A4 (enExample) |
| JP (1) | JP2020520917A (enExample) |
| KR (2) | KR20250037595A (enExample) |
| CN (1) | CN110996979A (enExample) |
| AU (2) | AU2018270092B2 (enExample) |
| BR (1) | BR112019024082A2 (enExample) |
| CA (1) | CA3064070A1 (enExample) |
| CO (1) | CO2019014212A2 (enExample) |
| MX (1) | MX2019013716A (enExample) |
| PH (1) | PH12019502578A1 (enExample) |
| RU (1) | RU2019141383A (enExample) |
| WO (1) | WO2018213710A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181869T1 (hr) * | 2009-10-21 | 2019-01-11 | Revance Therapeutics, Inc. | Metode i sustavi za pročišćavanje nekompleksiranog botulinskog neurotoksina |
| EP3675900A4 (en) | 2017-08-28 | 2021-05-05 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
| WO2022081736A1 (en) * | 2020-10-13 | 2022-04-21 | Revance Therapeutics, Inc. | Methods for treating cervical dystonia |
| CA3209156A1 (en) * | 2021-02-21 | 2022-08-25 | Revance Therapeutics, Inc. | Methods of and compositions for treatment of upper limb spasticity |
| WO2025059665A1 (en) | 2023-09-15 | 2025-03-20 | Revance Therapeutics, Inc. | Serial treatment with botulinum toxin for cervical dystonia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557256B2 (en) * | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| PT2985039T (pt) * | 2004-03-03 | 2018-11-09 | Revance Therapeutics Inc | Aplicação tópica e administração transdérmica de toxinas botulínicas |
| HUE037595T2 (hu) * | 2008-12-31 | 2018-09-28 | Revance Therapeutics Inc | Injektálható botulinum toxin készítmények |
| MX366344B (es) * | 2009-06-25 | 2019-07-05 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
| US8147848B2 (en) * | 2009-08-26 | 2012-04-03 | Allergan, Inc. | Method for treating premature ejaculation with a botulinum neurotoxin |
| ES2641068T3 (es) * | 2011-01-07 | 2017-11-07 | Revance Therapeutics, Inc. | Composición tópica que comprende una toxina botulínica y un colorante |
| AU2012283968B2 (en) * | 2011-07-20 | 2016-04-14 | Allergan, Inc. | Botulinum toxins for use in a method for treatment of adipose deposits |
| SG10202004337WA (en) | 2015-10-29 | 2020-06-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
| AU2018359962A1 (en) * | 2017-11-03 | 2020-05-28 | Revance Therapeutics, Inc. | Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect |
| WO2019113133A1 (en) * | 2017-12-04 | 2019-06-13 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration |
| RU2741221C1 (ru) | 2020-04-30 | 2021-01-22 | Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" (ФГАОУ ВО "КФУ им. В.И. Вернадского") | Способ комплексной реабилитации двигательной функции верхней конечности у больных детским церебральным параличом |
-
2018
- 2018-05-18 MX MX2019013716A patent/MX2019013716A/es unknown
- 2018-05-18 CN CN201880042201.4A patent/CN110996979A/zh active Pending
- 2018-05-18 KR KR1020257007090A patent/KR20250037595A/ko active Pending
- 2018-05-18 US US16/614,773 patent/US20200179498A1/en not_active Abandoned
- 2018-05-18 AU AU2018270092A patent/AU2018270092B2/en active Active
- 2018-05-18 RU RU2019141383A patent/RU2019141383A/ru unknown
- 2018-05-18 CA CA3064070A patent/CA3064070A1/en active Pending
- 2018-05-18 JP JP2019563463A patent/JP2020520917A/ja active Pending
- 2018-05-18 BR BR112019024082-9A patent/BR112019024082A2/pt unknown
- 2018-05-18 EP EP18802488.9A patent/EP3624819A4/en active Pending
- 2018-05-18 KR KR1020197037005A patent/KR102777928B1/ko active Active
- 2018-05-18 WO PCT/US2018/033397 patent/WO2018213710A1/en not_active Ceased
-
2019
- 2019-11-18 PH PH12019502578A patent/PH12019502578A1/en unknown
- 2019-12-16 CO CONC2019/0014212A patent/CO2019014212A2/es unknown
-
2021
- 2021-12-09 US US17/547,211 patent/US12257293B2/en active Active
-
2025
- 2025-03-24 US US19/088,478 patent/US20250319168A1/en active Pending
- 2025-07-16 AU AU2025205532A patent/AU2025205532A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250037595A (ko) | 2025-03-17 |
| PH12019502578A1 (en) | 2020-07-20 |
| RU2019141383A3 (enExample) | 2022-01-19 |
| CN110996979A (zh) | 2020-04-10 |
| EP3624819A4 (en) | 2021-03-24 |
| BR112019024082A2 (pt) | 2020-06-16 |
| US20220096610A1 (en) | 2022-03-31 |
| US12257293B2 (en) | 2025-03-25 |
| US20250319168A1 (en) | 2025-10-16 |
| JP2020520917A (ja) | 2020-07-16 |
| KR20200006587A (ko) | 2020-01-20 |
| KR102777928B1 (ko) | 2025-03-10 |
| AU2025205532A1 (en) | 2025-08-07 |
| MX2019013716A (es) | 2020-10-12 |
| AU2018270092B2 (en) | 2025-04-17 |
| WO2018213710A1 (en) | 2018-11-22 |
| EP3624819A1 (en) | 2020-03-25 |
| CA3064070A1 (en) | 2018-11-22 |
| US20200179498A1 (en) | 2020-06-11 |
| RU2019141383A (ru) | 2021-06-18 |
| AU2018270092A1 (en) | 2019-12-19 |
| NZ759612A (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019014212A2 (es) | Métodos de tratamiento para la distonía cervical listado de secuencias | |
| CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
| CL2017002066A1 (es) | Proteasas de cisteína | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX2016015126A (es) | Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas. | |
| MX2016014102A (es) | Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3. | |
| CR20190403A (es) | Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma | |
| EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
| CR20160485A (es) | Compuesto de ciclopropanamina y sus usos | |
| MX388562B (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| MX2019009783A (es) | Metodo para fabricar una barra que comprende antitranspirante. | |
| CL2023003217A1 (es) | Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer | |
| EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
| MX2017007000A (es) | Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas. | |
| MX2021008941A (es) | Moduladores gpr35. | |
| CO2019002245A2 (es) | Combinación de agonistas de fxr | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| MX2022013283A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| MX375924B (es) | Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo. | |
| BR112018011663A2 (pt) | toxina botulínica para distúrbios primários de humor e afetivos usando neurotransmissor | |
| MX2022013383A (es) | Composiciones y metodo para tratar la depresion. |